---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-035055"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-08-31T19:54:51+00:00"
generated_at: "2026-08-31T19:56:10.909515+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BridgeBio announces voluntary U.S. government agreement to expand Medicaid access, avoid pricing mandates

## Summary
- Voluntary agreement with U.S. government expands Medicaid access to Attruby via GENEROUS Model; specific terms confidential.
- BridgeBio expects no future pricing mandates; pricing commitments exclude medicines approved exclusively for orphan indications.
- CEO Neil Kumar joined President Trump at White House to announce deal; no impact on ForgingBridges copay program ($0/mo for qualifying patients).
- Three drugs under FDA review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 7, 2027), infigratinib for achondroplasia.

## SEC filing metadata
- accession: 0001140361-26-035055
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-08-31T19:54:51+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126035055/0001140361-26-035055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126035055/ef20081330_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-035055
- JSON: https://secwatch.observer/filing/0001140361-26-035055.json
- Plain text: https://secwatch.observer/filing/0001140361-26-035055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.